Recurrent Events in Survival Analysis
Comparison of risks of cardiovascular events in the elderly using standard survival analysis and multiple-events and recurrent-events methods
7
Dose response severity functions for acoustic disturbance in cetaceans using recurrent event survival analysis
14
Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland
7
Empirical study of correlated survival times for recurrent events with proportional hazards margins and the effect of correlation and censoring
10
Maitra_unc_0153D_17540.pdf
177
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
7
Original Article Time to relapse predicts post-relapse survival in recurrent osteosarcoma: a meta-analysis
9
The influence of life events on first and recurrent admissions in bipolar disorder
8
Recurrent Glioblastoma Multiforme—A Strategy for Long Term Survival
21
On reporting results from randomized controlled trials with recurrent events
12
Partnership formation and dissolution over the life course: applying sequence analysis and event history analysis in the study of recurrent events
25
Communication Sequences and Survival Analysis
13
A Phase II Study of Antineoplastons A10 and AS2 1 in Patients with Brainstem Gliomas The Report on Non Diffuse Intrinsic Pontine Glioma (Protocol BT 11)
11
Antidepressive Therapy in Myocardial Infarction, Prevents Recurrent Cardiovascular Events?
5
Outcome at 5 Years of Age of Children 23 to 27 Weeks’ Gestation: Refining the Prognosis
10
COMPARATIVE EVALUATION BETWEEN QUALITY OF LIFE (QOL), ADVERSE EVENTS AND SURVIVAL ANALYSIS OF ISCADOR FOR THE TREATMENT OF SOLID TUMORS
5
Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
11
Modelling recurrent events: comparison of statistical models with continuous and discontinuous risk intervals on recurrent malaria episodes data
9
Recurrent glomerulonephritis following renal transplantation and impact on graft survival
11
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
10